New research reveals that individuals who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on shed pounds much more quickly than those who end traditional diet and exercise plans.
Published data in a major health publication demonstrates that while overweight people often shed a large proportion of their body weight while on the medication, the mass is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"Users using such treatments need to be informed of the potential of quick weight regain when the medication is stopped," stated researcher Dr. Susan Jebb.
Such speed of recovery implies a reversion to pre-treatment weight within about a year and a half.
Weighing Approaches
The research, which reviewed dozens of studies involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with other pills.
Researchers emphasize that people who lose weight through dieting usually see a slower weight regain—approximately 100 grams monthly—after stopping.
Understanding the Fast Rebound
Nutrition scientists propose the way of the jabs is key to understanding the heightened rebound.
The injections imitate a natural hormone called GLP-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 levels far above than normal might result in the body to produce less of its endogenous GLP-1, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication leads to appetite is no longer kept in check, making excessive eating far more likely."
A Lifelong Issue?
Health authorities recommend the injections for individuals with weight-linked health risks, alongside prescribed lifestyle changes.
Many experts argue that, considering the high risk of relapse, the treatment should be considered long-term.
This view is echoed by pharmaceutical companies, who state that the results "underscore the persistent nature of obesity," akin to managing conditions like high blood pressure.
User Experiences
Individuals who have stopped the jabs explain a sudden return of appetite.
"I experienced a trigger activating and you're instantly ravenous," recalled an individual.
This challenge is worsened if users have not established lasting dietary or behavioural changes during therapy.
Significant Interest
Figures suggest that a significant number of adults in the UK have tried weight-loss jabs in the past year, with demand continuing to grow.
- Use is greater among females compared to men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the drugs through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a standalone fix and lasting health benefits relies on combined lifestyle support.
